Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate graves' orbitopathy treated with intravenous glucocorticoids

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 5, 2007, Pages 1653-1658

  Menconi, Francesca ^a   Marinò, Michele ^a   Pinchera, Aldo ^a   Rocchi, Roberto ^a   Mazzi, Barbara ^a   Nardi, Marco ^a   Bartalena, Luigi ^b   Marcocci, Claudio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; METHYLPREDNISOLONE ACETATE; THIAMAZOLE; THYROXINE; RADIOACTIVE IODINE; THYROID HORMONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG UPTAKE; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL MODEL; SUBTOTAL THYROIDECTOMY; THYROIDECTOMY; TREATMENT OUTCOME; BLOOD; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATIENT; PROSPECTIVE STUDY; THYROID GLAND;

ADULT; COMBINED MODALITY THERAPY; FEMALE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; INJECTIONS, INTRAVENOUS; IODINE RADIOISOTOPES; LINEAR MODELS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; THYROID GLAND; THYROID HORMONES; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 34249861894     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1800     Document Type: Article

References (20)

1. Bartalena L, Pinchera A, Marcocci C 2000 Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 21:168-199
2. Bartalena L, Wiersinga WM, Pinchera A 2004 Graves' ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 27:295-301
3. Bartalena L, Marcocci C, Tanda ML, Piantanida E, Lai A, Marinò M, Pinchera A 2005 An update on medical management of Graves' ophthalmopathy. J Endocrinol Invest 28:469-478
4. Ludgate M, Baker G 2004 Inducing Graves' ophthalmopathy. J Endocrinol Invest 27:211-215
5. Bahn RS 2004 TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthalmopathy. J Endocrinol Invest 27:216-220
6. Ajjan RA, Weetman AP 2004 New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy. J Endocrinol Invest 27:237-245
7. Prabhakar BS, Bahn RS, Smith TJ 2003 Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 24:802-835
8. Marcocci C, Marinò M, Rocchi R, Menconi F, Morabito E, Pinchera A 2004 Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy. J Endocrinol Invest 27:272-280
9. Marinò M, Chiovato L, Lisi S, Altea MA, Marcocci C, Pinchera A 2004 Role of thyroglobulin in the pathogenesis of Graves' ophthalmopathy: the hypothesis of Kriss revisited. J Endocrinol Invest 27:230-236
10. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L, Pinchera A 2003 Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Int Med 139:346-351
11. Catz B, Perzik SL 1969 Total thyroidectomy in the management of thyrotoxic and euthyroid Graves' disease. Am J Surg 118:434-438
12. Werner SC, Feind CR, Aida M 1967 Graves' disease and total thyroidectomy. Progression of severe eye changes and decrease in serum long acting thyroid stimulator after operation. N Engl J Med 276:132-138
13. De Groot LJ, Benjasuratwong Y 1996 Evaluation of thyroid ablative therapy for ophthalmopathy of Graves' disease. Orbit 15:187-196
14. Moleti M, Mattina F, Salamone I, Violi MA, Nucera C, Baldari S, Lo Schiavo MG, Regalbuto C, Trimarchi F, Vermiglio F 2003 Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves' ophthalmopathy. Thyroid 13:653-658
15. Pinchera A, Wiersinga W, Glinoer D, Kendall-Taylor P, Koorneef L, Marcocci C, Schleusener H, Romaldini J, Niepominiscze H, Nagataki S, Izumi M, Inoue M, Stockigt J, Wall J, Greenspan F, Solomon D, Garrity J, Gorman CA 1992 Classification of eye changes of Graves' disease. Thyroid 2:235-236
16. Bahn RS, Gorman CA 1987 Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am 16:391-407
17. Wiersinga WM 1998 Preventing Graves' ophthalmopathy. N Engl J Med 338:121-122
18. Marcocci C, Bartalena L, Pinchera A 1998 Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 21:468-471
19. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R 1990 Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 150:1098-1101
20. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M, Pinchera A 2001 Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86:3562-3567